Metastatic angiosarcoma is one of the most aggressive forms of a rare cancer, spreading from blood or lymph vessel linings to distant parts of the body. Understanding how doctors identify and track this disease is essential for anyone facing this diagnosis or supporting a loved one through treatment.

Introduction: Who Should Seek Diagnostic Testing

Anyone who notices unusual changes in their body should consider seeking medical attention, especially if certain warning signs appear. For angiosarcoma, this becomes particularly important if you notice a rapidly growing lump or bump under your skin, bruising that doesn’t fade or seems to spread over time, or discoloration that looks like a rash or bruise but continues to grow larger. These symptoms deserve prompt evaluation by a healthcare provider.^[1]

People who have received radiation therapy in the past face higher risk and should remain especially vigilant. This is particularly true for breast cancer survivors who received radiation to the chest wall, as radiation-induced angiosarcoma can develop years after treatment—typically around eight to ten years later. Similarly, individuals with chronic swelling due to fluid accumulation in their tissues, a condition called lymphedema, should watch for any skin changes in the affected area. Those who have been exposed to certain chemicals in their workplace, such as vinyl chloride, arsenic, or thorium dioxide, also carry increased risk.^[1][6]

When angiosarcoma has already been diagnosed and treated, regular follow-up becomes crucial. Since this cancer has a high tendency to return and spread to other parts of the body, ongoing monitoring helps catch any recurrence early. Most cases of recurrence happen within the first 24 months after local treatment, making this period especially important for careful surveillance.^[1]

If angiosarcoma develops in internal organs rather than on the skin, symptoms may not appear until the tumor grows large enough to interfere with how that organ works or creates pressure on nearby structures. You might experience persistent fatigue, unexplained weight loss, general feelings of unwellness, or pain near the affected area. For instance, if the tumor is in the liver, you might notice pain in the upper part of your belly along with yellowing of your skin and eyes, a condition called jaundice.^[1]

Diagnostic Methods for Identifying Angiosarcoma

The journey to diagnosing angiosarcoma typically begins with a thorough physical examination. Your healthcare provider will carefully examine you to understand your condition, looking at any visible changes in your skin or feeling for lumps or swelling. They will also take a detailed medical history, asking about previous radiation treatments, exposure to chemicals, chronic swelling, and any family history of cancer or genetic conditions.^[1][12]

Biopsy: The Definitive Test

While imaging tests provide valuable information, the final diagnosis of angiosarcoma requires pathological and immunohistochemical confirmation through a biopsy. This means that doctors must examine actual tissue from the suspected tumor under a microscope to make a certain diagnosis. During a biopsy, your provider removes a small sample of the suspicious tissue for laboratory testing. The sample is then sent to a laboratory where specialists examine it to detect cancer cells and determine their specific characteristics.^[1][12]

The laboratory tests go beyond simply looking at cells under a microscope. Special tests called immunohistochemistry help identify specific markers on the cells that confirm they are angiosarcoma cells rather than another type of cancer. These tests can also provide information about how aggressive the cancer is and what treatment approaches might work best. This detailed analysis is essential because angiosarcoma can look similar to other types of tumors, and accurate identification guides the entire treatment plan.^[1]

Imaging Studies

Several imaging techniques help doctors understand the extent of the disease and whether it has spread beyond its original location. Ultrasound uses sound waves to create pictures of the inside of your body and is often one of the first imaging tests performed, especially for tumors near the skin surface or in organs like the liver. It’s painless and doesn’t use radiation, making it a safe initial screening tool.^[1]

Computed tomography, commonly called a CT scan, plays an important role in evaluating metastatic disease. This imaging technique combines X-ray images taken from different angles and uses computer processing to create cross-sectional views of bones, blood vessels, and soft tissues. CT scans are particularly valuable for detecting whether angiosarcoma has spread to the lungs, which is a common site of metastasis. They can identify characteristic features such as cystic lung nodules surrounded by areas of haziness called ground-glass changes, which are typical patterns of metastatic angiosarcoma.^[1][8]

Magnetic resonance imaging, or MRI, is the preferred method for assessing localized disease both before and after treatment. MRI uses powerful magnets and radio waves to create detailed images of your body’s soft tissues without using radiation. It excels at showing the extent of the primary tumor, how many separate areas of disease exist, and whether the cancer has invaded adjacent structures. This information is crucial when doctors are planning surgery or other local treatments. MRI is complementary to CT scanning, with each technique offering different advantages depending on what needs to be examined.^[1][8]

Other imaging tests may include positron emission tomography (PET scan), which helps detect cancer cells throughout the body by showing areas with high metabolic activity, and bone scans if there’s concern about spread to the bones. The choice of which imaging studies to perform depends on your specific situation, where the primary tumor is located, and what symptoms you’re experiencing.^[5][12]

Blood and Laboratory Tests

While there is no specific blood test that can diagnose angiosarcoma, doctors may order various blood and urine tests as part of the overall evaluation. These tests help assess your general health, check how well your organs are functioning, and establish baseline measurements before treatment begins. Some blood tests can reveal markers of inflammation or other changes that might be related to the cancer. Although these tests don’t diagnose angiosarcoma directly, they provide important context for treatment planning.^[7]

Staging the Disease

Once angiosarcoma is confirmed, doctors work to determine its stage, which describes how far the cancer has spread. Staging involves combining information from physical examination, biopsy results, and all imaging studies. Angiosarcoma can be classified from stage 1 to stage 4. In stage 1, the tumor is relatively small and contained where it started. Stage 2 means the tumor is larger but hasn’t spread to surrounding tissue—both of these are considered low-grade. Stage 3 indicates the tumor has grown larger and begun spreading into nearby tissues. Stage 4, also called metastatic cancer, means the disease has spread from where it started to other organs or sites in the body, and both stage 3 and 4 are considered high-grade tumors.^[7]

For metastatic angiosarcoma specifically, identifying where the cancer has spread is essential. Common sites of metastasis include the lungs, liver, bones, and brain. Among patients with metastatic disease, studies have found that approximately 60% have spread to the lungs, 30% to the liver, 43% to bone, and 9% to the brain. More than one-third of patients have cancer in two or more distant sites at the time of diagnosis.^[4]

Diagnostics for Clinical Trial Qualification

Clinical trials offer access to new treatments that may not yet be widely available, and participation requires meeting specific criteria established by researchers. If you’re considering joining a clinical trial for metastatic angiosarcoma, you’ll undergo additional testing beyond standard diagnostic procedures to determine whether you qualify.

Most clinical trials require confirmed diagnosis through biopsy with pathological examination showing that you have angiosarcoma specifically, not another type of cancer. The biopsy report must clearly document the cancer’s characteristics, including its grade and specific cell markers identified through immunohistochemistry. This confirmation ensures that the trial is studying the intended disease and that results will be meaningful.^[1]

Baseline imaging studies are typically required before you can enroll in a trial. These include CT scans of the chest, abdomen, and pelvis to document all sites of disease and measure the size of tumors. Having accurate measurements at the start allows researchers to determine later whether the treatment is working. Some trials may also require MRI scans, particularly if there’s concern about disease in the brain or if the primary tumor is in a location better visualized by MRI.^[8]

Blood tests are standard requirements for clinical trial entry. Researchers need to verify that your major organs—especially your liver, kidneys, and bone marrow—are functioning well enough to tolerate the experimental treatment. Common tests include a complete blood count to check your red blood cells, white blood cells, and platelets; liver function tests to measure enzymes and proteins that indicate liver health; kidney function tests to ensure your kidneys can process medications; and sometimes tests to check your heart function if the treatment might affect the heart.^[4]

Some clinical trials studying targeted therapies or immunotherapy may require additional specialized testing. For example, if a trial is investigating a drug that targets specific genetic changes, you may need genetic testing of your tumor tissue to see if it has the mutations the drug is designed to attack. Research has identified recurrent mutations in genes including KDR, TP53, and PIK3CA in angiosarcoma patients, and trials targeting these pathways may screen for these specific changes. Similarly, trials testing immune checkpoint inhibitors—drugs that help your immune system fight cancer—may test whether your tumor expresses certain proteins like PD-L1 that predict response to these treatments.^[1][13]

Performance status assessment is another standard element of trial qualification. This evaluation measures how well you can perform daily activities and care for yourself, typically using a standardized scale. Trials generally require that participants be well enough to tolerate treatment and follow the study protocol, though the specific requirements vary between trials.